Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Midcap & smallcap buck trend
Tue, 5 Nov 01:30 pm

Indian share markets regained some lost ground but continued to trade in the negative territory in the post-noon trading session. Majority of the sectoral indices are trading in the red with FMCG, pharma and IT stocks being the biggest losers. Realty, banking and auto are among the stocks trading in the green.

BSE-Sensex is down 136 points and NSE-Nifty is trading 29 points down. BSE Mid Cap is trading up 1% and BSE Small Cap index is trading down 0.8%. The rupee is trading at 61.7 to the US dollar.

FMCG stocks are trading in the green with Lakshmi Energy and Paper Products being the biggest gainers whereas Dabur and Godrej Consumer Products are among the major losers. As per a leading financial daily, Marico is planning to expand the smaller retail format of Kaya Skin Bar to metropolitan cities. Kaya Skin Bar, that occupies less than half the space of Kaya Skin Clinic, sells skincare products. Presently there are three such stores in Bangalore as compared to 83 Kaya Skin Clinics that offer technology-intensive cosmetic dermatological services. The company wants to become an end-to-end solution provider in the skincare business. Currently skincare products contribute only 20% to overall Kaya revenues with the balance coming from services. Earlier, Marico demerged its Kaya skincare division into a separate entity Marico Kaya Enterprises (MAKE) to consolidate its FMCG business in India and overseas. Kaya currently contributes 7% to Marico's consolidated sales. Marico's stock is currently trading marginally down.

Most of the Indian pharma stocks are trading in green, with Orchid chemicals and Indoco remedies being the leading gainers. As per the financial daily, Department of Pharmaceuticals (DoP) has rejected the review petition filed by Cadila healthcare. The company had filed petition challenging the price fixation done by the National Pharmaceutical Pricing Authority (NPPA) in case of its eight formulations. Recently, the DoP had rejected the petition on the ground that it lacked any merit. Reportedly, Cadila challenged the ceiling price fixed on eight drugs viz; for folic acid tablet (5 mg), losartan potassium tablets (25 mg), losartan potassium tablets (50 mg), pantoprazol injection (40 mg), norethisterone tablets (5 mg), atenolol tablets (50 mg), atorvastatin tablets (10 mg), and omeprazole capsules (20 mg). It should be noted that several companies have filed similar litigations, challenging the new prices on various drugs. However, the department has rejected several such petitions. Cadila is trading up by 1.86%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary


What else is happening in the markets today? Dig in...

Equitymaster requests your view! Post a comment on "Midcap & smallcap buck trend". Click here!

  

Related Views on News

MARICO Announces Quarterly Results (3QFY21); Net Profit Up 13.0% (Quarterly Result Update)

Jan 28, 2021 | Updated on Jan 28, 2021

For the quarter ended December 2020, MARICO has posted a net profit of Rs 3 bn (up 13.0% YoY). Sales on the other hand came in at Rs 21 bn (up 16.3% YoY). Read on for a complete analysis of MARICO's quarterly results.

MARICO 2019-20 Annual Report Analysis (Annual Result Update)

Dec 28, 2020 | Updated on Dec 28, 2020

Here's an analysis of the annual report of MARICO for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of MARICO. Also includes updates on the valuation of MARICO.

MARICO Announces Quarterly Results (2QFY21); Net Profit Up 8.3% (Quarterly Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

For the quarter ended September 2020, MARICO has posted a net profit of Rs 3 bn (up 8.3% YoY). Sales on the other hand came in at Rs 20 bn (up 8.7% YoY). Read on for a complete analysis of MARICO's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market (Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

Charge Your Portfolio with this Smallcap Proxy Play on India's EV Revolution (Profit Hunter)

Mar 5, 2021

This could be the biggest wealth creator of the decade.

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE FMCG


Mar 8, 2021 (Close)

S&P BSE FMCG 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS